Đang chuẩn bị liên kết để tải về tài liệu:
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

After analysis of minor RAS mutations (KRAS exon 3, 4/NRAS) in the FIRE-3 and PRIME studies, an expanded range of RAS mutations were established as a negative predictive marker for the efficacy of anti-EGFR antibody treatment. BRAF and PIK3CA mutations may be candidate biomarkers for anti-EGFR targeted therapies. |

TÀI LIỆU LIÊN QUAN

Association of breastfeeding and postmenopausal osteoporosis in Chinese women: A community-based retrospective study

Comparison of different media for germ tube production by candida albicans: A retrospective study

Assessment of effect modification of statins on new-onset diabetes based on various medical backgrounds: A retrospective cohort study

A retrospective study on consequences of cesarean section in bovine

A retrospective study on patients with breast cancer curatively treated at Hue University hospital from 2013-2016

Development and validation of a nomogram for predicting late-onset sepsis in preterm infants on the basis of thyroid function and other risk factors: Mixed retrospective and prospective cohort study

Sevoflurane with opioid or dexmedetomidine infusions in dogs undergoing intracranial surgery: A retrospective observational study

Correlation between kidney transplantation and colorectal cancer in hemodialysis patients: A nationwide, retrospective, population-based cohort study

Outcome after resection of Adrenocortical Carcinoma liver metastases: A retrospective study

Survival predictors of metastatic angiosarcomas: A surveillance, epidemiology, and end results program population-based retrospective study